Home  /  Resource Library  /  Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study

Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study

Results of a study investigating ibrutinib combined with rituxiamb and lenalidomide for first line treatment of older patients with DLBCL.